The effects of metabolic parameters of aripiprazole in patients with schizophrenia.

Trial Profile

The effects of metabolic parameters of aripiprazole in patients with schizophrenia.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Feb 2017 Last checked against ClinicalTrials.gov record.
    • 17 Jun 2009 Planned end date changed from 1 Sep 2009 to 1 Oct 2009 as reported by ClinicalTrials.gov.
    • 14 Jul 2008 Status changed from in progress to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top